A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status After Recurrence of Resectable Gastric Cancer

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2020 Jul 1

PMID 32599987

Citations 14

Authors

Ji Yeong An

Yoon Young Choi

Jeeyun Lee

Woo Jin Hyung

Kyoung-Mee Kim

Sung Hoon Noh

Min-Gew Choi

Jae-Ho Cheong

Affiliations

Soon will be listed here.

Abstract

Purpose: High microsatellite instability (MSI) is related to good prognosis in gastric cancer. We aimed to identify the prognostic factors of patients with recurrent gastric cancer and investigate the role of MSI as a prognostic and predictive biomarker of survival after tumor recurrence.

Materials And Methods: This retrospective cohort study enrolled patients treated for stage II/III gastric cancer who developed tumor recurrence and in whom the MSI status or mismatch repair (MMR) status of the tumor was known. MSI status and the expression of MMR proteins were evaluated using polymerase chain reaction and immunohistochemical analysis, respectively.

Results: Of the 790 patients included, 64 (8.1%) had high MSI status or MMR deficiency. The tumor-node-metastasis stage, type of recurrence, Lauren classification, chemotherapy after recurrence, and interval to recurrence were independently associated with survival after tumor recurrence. The MSI/MMR status and receiving adjuvant chemotherapy were not associated with survival after recurrence. In a subgroup analysis of patients with high MSI or MMR-deficient gastric cancer, those who did not receive adjuvant chemotherapy had better treatment response to chemotherapy after recurrence than those who received adjuvant chemotherapy.

Conclusion: Patients with high MSI/MMR-deficient gastric cancer should be spared from adjuvant chemotherapy after surgery, but aggressive chemotherapy after recurrence should be considered. Higher tumor-node-metastasis stage, Lauren classification, interval to recurrence, and type of recurrence are associated with survival after tumor recurrence and should thus be considered when establishing a treatment plan and designing clinical trials targeting recurrent gastric cancer.

Citing Articles

Clinicopathological features and prognostic significance of TAF1L in gastric cancer.

Chen H, Chen H, Fang J, Huang X, Zhu X, Chai T BMC Gastroenterol. 2024; 24(1):445.

PMID: 39623292 PMC: 11613484. DOI: 10.1186/s12876-024-03534-y.

HIGD1B, as a novel prognostic biomarker, is involved in regulating the tumor microenvironment and immune cell infiltration; its overexpression leads to poor prognosis in gastric cancer patients.

Wang S, Zhang S, Li X, Li X, Zhao S, Guo J Front Immunol. 2024; 15:1415148.

PMID: 39108265 PMC: 11300267. DOI: 10.3389/fimmu.2024.1415148.

Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair.

Ooki A, Osumi H, Yoshino K, Yamaguchi K Gastric Cancer. 2024; 27(5):907-931.

PMID: 38922524 PMC: 11335850. DOI: 10.1007/s10120-024-01523-4.

Role of Recurrence Pattern Multiplicity in Predicting Post-recurrence Survival in Patients Who Underwent Curative Gastrectomy for Gastric Cancer.

Yang J, Park J, Choi S, Lee W J Gastric Cancer. 2024; 24(2):231-242.

PMID: 38575515 PMC: 10995828. DOI: 10.5230/jgc.2024.24.e18.

Genomic and evolutionary characteristics of metastatic gastric cancer by routes.

Lee J, Kim K, Shin S, Cheong J, Choi Y Br J Cancer. 2023; 129(4):672-682.

PMID: 37422528 PMC: 10421927. DOI: 10.1038/s41416-023-02338-3.

References

Choi Y, Kim H, Shin S, Kim H, Lee J, Yang H . Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg. 2018; 270(2):309-316. DOI: 10.1097/SLA.0000000000002803. View

Boland C, Thibodeau S, Hamilton S, Sidransky D, Eshleman J, Burt R . A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58(22):5248-57. View

Cheong J, Yang H, Kim H, Kim W, Kim Y, Kook M . Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol. 2018; 19(5):629-638. DOI: 10.1016/S1470-2045(18)30108-6. View

. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer. 2019; 19(1):1-48. PMC: 6441770. DOI: 10.5230/jgc.2019.19.e8. View

Chiaravalli A, Feltri M, Bertolini V, Bagnoli E, Furlan D, Cerutti R . Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch. 2005; 448(3):344-53. DOI: 10.1007/s00428-005-0066-4. View

Jung K, Won Y, Kong H, Lee E . Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016. Cancer Res Treat. 2019; 51(2):417-430. PMC: 6473271. DOI: 10.4143/crt.2019.138. View

OConnell M, Campbell M, Goldberg R, Grothey A, Seitz J, Benedetti J . Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008; 26(14):2336-41. DOI: 10.1200/JCO.2007.15.8261. View

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

Cho J, Lee J, Bang H, Kim S, Park S, An J . Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget. 2017; 8(8):13320-13328. PMC: 5355099. DOI: 10.18632/oncotarget.14519. View

10.

Kim S, Choi Y, An J, Shin H, Jo A, Choi H . The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses. Int J Cancer. 2015; 137(4):819-25. DOI: 10.1002/ijc.29449. View

11.

Choi Y, Cheong J . Comment on "To Treat, or Not to Treat, That is the Question: Biomarker-guided Adjuvant Chemotherapy for Stage II and III Gastric Cancer". Ann Surg. 2018; 270(2):e40-e41. DOI: 10.1097/SLA.0000000000003102. View

12.

Grogg K, Lohse C, Pankratz V, Halling K, Smyrk T . Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol. 2003; 16(7):641-51. DOI: 10.1097/01.MP.0000076980.73826.C0. View

13.

Sinicrope F, Shi Q, Allegra C, Smyrk T, Thibodeau S, Goldberg R . Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol. 2016; 3(4):472-480. PMC: 5498991. DOI: 10.1001/jamaoncol.2016.5469. View

14.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

15.

Noh S, Park S, Yang H, Chung H, Chung I, Kim S . Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15(12):1389-96. DOI: 10.1016/S1470-2045(14)70473-5. View

16.

Cho J, Kang S, Kim K . MMR protein immunohistochemistry and microsatellite instability in gastric cancers. Pathology. 2018; 51(1):110-113. DOI: 10.1016/j.pathol.2018.09.057. View

17.

. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016; 20(1):1-19. PMC: 5215069. DOI: 10.1007/s10120-016-0622-4. View

18.

Smyth E, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z . Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017; 3(9):1197-1203. PMC: 5824280. DOI: 10.1001/jamaoncol.2016.6762. View

19.

Roh C, Choi Y, Choi S, Seo W, Cho M, Jang E . Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial. Yonsei Med J. 2019; 60(2):132-139. PMC: 6342711. DOI: 10.3349/ymj.2019.60.2.132. View

20.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View